1800-272-662
Shopping Cart 0
countryflagAU
Login

Inhalerx Ltd

Healthcare AU IRX

0.0235AUD
0.0025(11.90%)

Last update at 2026-03-11T23:00:00Z

Day Range

0.020.02
LowHigh

52 Week Range

0.020.05
LowHigh

Fundamentals

  • Previous Close 0.02
  • Market Cap6.90M
  • Volume55310
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-1.41374M
  • Revenue TTM0.83M
  • Revenue Per Share TTM0.004
  • Gross Profit TTM 0.83M
  • Diluted EPS TTM-0.01

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -1.27609M -2.64732M -1.89661M -1.11113M -1.01134M
Minority interest - - - - -
Net income -1.27609M -1.44327M -1.89661M -1.11113M -1.01134M
Selling general administrative 0.83M 0.83M 0.51M 0.56M 0.31M
Selling and marketing expenses 0.06M 0.03M 0.03M 0.05M 0.04M
Gross profit 0.34M 1.20M 0.02M 0.05M -0.02643M
Reconciled depreciation - - 0.00052M 0.00181M -
Ebit - -1.42345M -1.92366M -1.12590M -1.20557M
Ebitda - -1.41374M -1.92314M -1.12409M -1.02120M
Depreciation and amortization 1.35M 0.00971M 0.00052M 0.00181M -
Non operating income net other - - - - -
Operating income -1.32713M -1.38649M -1.92366M -1.12590M -1.02120M
Other operating expenses 1.66M 2.59M 1.95M 1.29M 1.12M
Interest expense 0.09M 0.00810M - 0.00000M 0.00000M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.00365M 0.00203M 0.02M 0.00033M 0.00029M
Net interest income -0.08427M -0.00608M 0.02M 0.00033M 0.00029M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.40181M -1.20405M -0.01613M -0.00033M -
Total revenue 0.34M 1.20M 0.02M 0.17M 0.10M
Total operating expenses 1.66M 2.59M 1.95M 1.18M 0.99M
Cost of revenue - - 0.00000M 0.12M 0.12M
Total other income expense net 0.05M -1.26083M 0.01M 0.01M 0.00957M
Discontinued operations - - - - -
Net income from continuing ops -1.20937M -1.44327M -1.89661M -1.11113M -1.20528M
Net income applicable to common shares -1.20937M -1.44327M -1.92705M -1.11113M -1.20528M
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 0.65M 1.58M 2.26M 2.93M 1.90M
Intangible assets - - 0.01M 0.01M 0.00430M
Earning assets - - - - -
Other current assets 0.45M 0.06M -0.00000M 0.00108M 0.00240M
Total liab 0.78M 0.91M 0.36M 0.25M 0.58M
Total stockholder equity -0.13068M 1.00M 1.90M 2.68M 1.32M
Deferred long term liab - - - - -
Other current liab 0.17M 0.17M 0.26M 0.18M 0.46M
Common stock 14.53M 14.08M 13.93M 12.90M 10.56M
Capital stock - - 13.93M 12.90M 10.45M
Retained earnings -14.44525M -13.16916M -11.69545M -9.25430M -7.94924M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 0.19M 0.72M 2.13M 2.80M 1.72M
Cash and equivalents - - 2.13M 2.80M 1.72M
Total current liabilities 0.78M 0.91M 0.36M 0.25M 0.58M
Current deferred revenue - - - - -
Net debt -0.16085M -0.15554M -2.13339M -2.80348M -1.71948M
Short term debt 0.03M 0.56M 0.00000M 0.00000M 0.00000M
Short long term debt - - - - -
Short long term debt total 0.03M 0.56M - - -
Other stockholder equity 0.00000M - -0.02523M -0.96899M -0.29476M
Property plant equipment - - 0.00000M 0.00971M -
Total current assets 0.65M 1.58M 2.24M 2.91M 1.90M
Long term investments - - - - -
Net tangible assets - - 1.91M 2.66M 1.32M
Short term investments - - - - -
Net receivables - 0.80M 0.03M 0.02M 0.12M
Long term debt - - - - -
Inventory - - 0.08M 0.02M 0.04M
Accounts payable 0.57M 0.18M 0.10M 0.07M 0.12M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.21261M 0.09M -0.30408M -0.96899M -0.98781M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total - - 0.01M 0.02M 0.00430M
Capital lease obligations - - - - -
Long term debt total - - 0.00000M 0.00000M 0.00000M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments 0.00000M - -0.00017M -0.02509M -0.00430M
Change to liabilities - - 0.08M -0.11604M 0.10M
Total cashflows from investing activities 0.00000M 0.00000M -0.00018M -0.02509M -0.00430M
Net borrowings -0.14579M 0.55M - - -
Total cash from financing activities -0.15214M 0.54M 1.18M 2.26M 2.37M
Change to operating activities - - -0.01439M 0.04M -0.07066M
Net income -1.27609M -1.44327M -1.89661M -1.11113M -1.20528M
Change in cash -0.52090M -1.41757M -0.67009M 1.08M 1.29M
Begin period cash flow 0.72M 2.13M 2.80M 1.72M 0.42M
End period cash flow 0.19M 0.72M 2.13M 2.80M 1.72M
Total cash from operating activities -0.36877M -1.96186M -1.84630M -1.14857M -1.04924M
Issuance of capital stock - - 1.20M 2.27M 2.41M
Depreciation - - 0.00052M 0.00181M 0.00181M
Other cashflows from investing activities 0.00000M - - - -
Dividends paid - - - - -
Change to inventory - - - -0.02060M -0.02060M
Change to account receivables 0.36M -0.77068M - 0.06M 0.09M
Sale purchase of stock -0.00635M -0.00154M -0.02362M -0.01377M 2.41M
Other cashflows from financing activities -0.54679M -0.00154M -0.00017M -0.02509M -0.03653M
Change to netincome - - 0.05M 0.00430M 0.03M
Capital expenditures 0.00000M 0.00000M 0.00017M 0.03M 0.00430M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.76M -0.59081M 0.02M 0.00033M 0.01M
Stock based compensation 0.02M 0.06M - - -
Other non cash items 0.15M 0.07M - - -
Free cash flow -0.36877M -1.96186M -0.00017M -0.02509M -0.00430M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
IRX
Inhalerx Ltd		 0.0025 11.90% 0.02 - - 8.27 8.55 273.62 -3.5284
CSL
CSL Ltd		 -0.01 0.0071% 141.03 16.27 19.23 4.44 2.61 3.90 11.73
TLX
TELIX Pharmaceuticals Ltd		 0.06 0.53% 11.29 - 1111.11 4.73 6.52 3.77 86.30
MSB
Mesoblast Ltd		 -0.03 1.40% 2.11 - 454.55 41.58 3.42 30.11 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.19 1.59% 11.76 51.13 44.25 23.04 4.47 18.83 55.27

Reports Covered

Stock Research & News

View All

Profile

Nexalis Therapeutics Limited, a biotechnology company, develops and sells registrable inhaled drug-device combinations in Australia. It is developing IRX-211 that has completed Phase 1 clinical trial for the treatment of Breakthrough Cancer Pain (BTcP); and IRX-616a that is in preclinical trial for panic disorder (PD). The company was formerly known as InhaleRx Limited and changed its name Nexalis Therapeutics Limited in January 2026. Nexalis Therapeutics Limited was incorporated in 2016 and is headquartered in Melbourne, Australia.

Inhalerx Ltd

505 Little Collins Street, Melbourne, VIC, Australia, 3000

Key Executives

Name Title Year Born
Mr. Darryl Davies Chief Exec. Officer NA
Dr. Robert Jenny Ph.D. Chief Scientific Officer NA
Mr. Srinivasa Rao Suryadevara Exec. VP 1968
Ms. Nova Anne Taylor Company Sec. NA
Ms. Elizabeth Spooner Joint Company Sec. NA
Mr. Darryl Davies B.Sc. Chief Executive Officer NA
Dr. Robert Jenny B.A., B.Sc., Ph.D. Chief Scientific Officer NA
Mr. Srinivasa Rao Suryadevara Executive Vice President 1968
Mr. James Stephen Barrie CPA Company Secretary NA
Mr. Darryl Davies B.Sc. Chief Executive Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.